Base de dados : MEDLINE
Pesquisa : E01.370.390 [Categoria DeCS]
Referências encontradas : 730 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 73 ir para página                         

  1 / 730 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28973248
[Au] Autor:Wallis CJD; Juvet T; Lee Y; Matta R; Herschorn S; Kodama R; Kulkarni GS; Satkunasivam R; Geerts W; McLeod A; Narod SA; Nam RK
[Ad] Endereço:Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:Association Between Use of Antithrombotic Medication and Hematuria-Related Complications.
[So] Source:JAMA;318(13):1260-1271, 2017 10 03.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Antithrombotic medications are among the most commonly prescribed medications. Objective: To characterize rates of hematuria-related complications among patients taking antithrombotic medications. Design, Setting, and Participants: Population-based, retrospective cohort study including all citizens in Ontario, Canada, aged 66 years and older between 2002 and 2014. The final follow-up date was December 31, 2014. Exposures: Receipt of an oral anticoagulant or antiplatelet medication. Main Outcomes and Measures: Hematuria-related complications, defined as emergency department visit, hospitalization, or a urologic procedure to investigate or manage gross hematuria. Results: Among 2 518 064 patients, 808 897 (mean [SD] age, 72.1 [6.8] years; 428 531 [53%] women) received at least 1 prescription for an antithrombotic agent over the study period. Over a median follow-up of 7.3 years, the rates of hematuria-related complications were 123.95 events per 1000 person-years among patients actively exposed to antithrombotic agents vs 80.17 events per 1000 person-years among patients not exposed to these drugs (difference, 43.8; 95% CI, 43.0-44.6; P < .001, and incidence rate ratio [IRR], 1.44; 95% CI, 1.42-1.46). The rates of complications among exposed vs unexposed patients (80.17 events/1000 person-years) were 105.78 for urologic procedures (difference, 33.5; 95% CI, 32.8-34.3; P < .001, and IRR, 1.37; 95% CI, 1.36-1.39), 11.12 for hospitalizations (difference, 5.7; 95% CI, 5.5-5.9; P < .001, and IRR, 2.03; 95% CI, 2.00-2.06), and 7.05 for emergency department visits (difference, 4.5; 95% CI, 4.3-4.7; P < .001, and IRR, 2.80; 95% CI, 2.74-2.86). Compared with patients who were unexposed to thrombotic agents, the rates of hematuria-related complications were 191.61 events per 1000 person-years (difference, 117.3; 95% CI, 112.8-121.8) for those exposed to both an anticoagulant and antiplatelet agent (IRR, 10.48; 95% CI, 8.16-13.45), 140.92 (difference, 57.7; 95% CI, 56.9-58.4) for those exposed to anticoagulants (IRR, 1.55; 95% CI, 1.52-1.59), and 110.72 (difference, 26.5; 95% CI, 25.9-27.0) for those exposed to antiplatelet agents (IRR, 1.31; 95% CI, 1.29-1.33). Patients exposed to antithrombotic agents, compared with patients not exposed to these drugs, were more likely to be diagnosed as having bladder cancer within 6 months (0.70% vs 0.38%; odds ratio, 1.85; 95% CI, 1.79-1.92). Conclusions and Relevance: Among older adults in Ontario, Canada, use of antithrombotic medications, compared with nonuse of these medications, was significantly associated with higher rates of hematuria-related complications (including emergency department visits, hospitalizations, and urologic procedures to manage gross hematuria).
[Mh] Termos MeSH primário: Anticoagulantes/efeitos adversos
Fibrilação Atrial/tratamento farmacológico
Hematúria/induzido quimicamente
Inibidores da Agregação de Plaquetas/efeitos adversos
[Mh] Termos MeSH secundário: Administração Oral
Idoso
Idoso de 80 Anos ou mais
Anticoagulantes/uso terapêutico
Fibrilação Atrial/complicações
Técnicas de Diagnóstico Urológico
Feminino
Hematúria/terapia
Hospitalização
Seres Humanos
Masculino
Ontário
Inibidores da Agregação de Plaquetas/uso terapêutico
Estudos Retrospectivos
Neoplasias da Bexiga Urinária/complicações
Neoplasias da Bexiga Urinária/diagnóstico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Platelet Aggregation Inhibitors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171004
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.13890


  2 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28411912
[Au] Autor:Haifler M; Kutikov A
[Ad] Endereço:Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University Health System, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
[Ti] Título:Current Role of Renal Biopsy in Urologic Practice.
[So] Source:Urol Clin North Am;44(2):203-211, 2017 May.
[Is] ISSN:1558-318X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Most small renal masses (SRMs) are indolent. In fact, only approximately 80% of SRMs are malignant. Furthermore, SRMs are commonly detected in elderly and comorbid patients. Therefore, opportunities for better care intensity calibration exist. Renal mass biopsy (RMB), when appropriately used, is a valuable clinical tool to help with critical clinical decision-making in patients with SRM. This article summarizes the role of modern RMB in helping gauge care for patients with SRM.
[Mh] Termos MeSH primário: Neoplasias Renais/patologia
[Mh] Termos MeSH secundário: Biópsia/métodos
Tomada de Decisão Clínica
Diagnóstico Diferencial
Técnicas de Diagnóstico Urológico
Seres Humanos
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170427
[Lr] Data última revisão:
170427
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170417
[St] Status:MEDLINE


  3 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28345769
[Au] Autor:Cameron AP; Campeau L; Brucker BM; Clemens JQ; Bales GT; Albo ME; Kennelly MJ
[Ad] Endereço:Department of Urology, University of Michigan, Ann Arbor, Michigan.
[Ti] Título:Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient.
[So] Source:Neurourol Urodyn;36(4):915-926, 2017 04.
[Is] ISSN:1520-6777
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIMS: Antibiotic prophylaxis before urodynamic testing (UDS) is widely utilized to prevent urinary tract infection (UTI) with only limited guidance. The Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) convened a Best Practice Policy Panel to formulate recommendations on the urodynamic antibiotic prophylaxis in the non-index patient. METHODS: Recommendations are based on a literature review and the Panel's expert opinion, with all recommendations graded using the Oxford grading system. RESULTS: All patients should be screened for symptoms of UTI and undergo dipstick urinalysis. If the clinician suspects a UTI, the UDS should be postponed until it has been treated. The first choice for prophylaxis is a single oral dose of trimethoprim-sulfamethoxazole before UDS, with alternative antibiotics chosen in case of allergy or intolerance. Individuals who do NOT require routine antibiotic prophylaxis include those without known relevant genitourinary anomalies, diabetics, those with prior genitourinary surgery, a history of recurrent UTI, post-menopausal women, recently hospitalized patients, patients with cardiac valvular disease, nutritional deficiencies or obesity. Identified risk factors that increase the potential for UTI following UDS and for which the panel recommends peri-procedure antibiotics include: known relevant neurogenic lower urinary tract dysfunction, elevated PVR, asymptomatic bacteriuria, immunosuppression, age over 70, and patients with any indwelling catheter, external urinary collection device, or performing intermittent catheterization. Patients with orthopedic implants have a separate risk stratification. CONCLUSIONS: These recommendations can assist urodynamic providers in the appropriate use of antibiotics for UDS testing. Clinical judgment of the provider must always be considered.
[Mh] Termos MeSH primário: Antibioticoprofilaxia
Técnicas de Diagnóstico Urológico/efeitos adversos
Infecções Urinárias/etiologia
Infecções Urinárias/prevenção & controle
[Mh] Termos MeSH secundário: Antibioticoprofilaxia/efeitos adversos
Seres Humanos
Guias de Prática Clínica como Assunto
Urodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1002/nau.23253


  4 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28221143
[Au] Autor:Lancina Martín JA
[Ad] Endereço:Unidad de Litiasis. Servicio de Urología. Complejo Hospitalario Universitario de A Coruña. España.
[Ti] Título:[Metabolic study. How to make it accessible, useful and generalized.]
[Ti] Título:Estudio metabólico. Cómo hacerlo accesible, útil y generalizado..
[So] Source:Arch Esp Urol;70(1):71-90, 2017 Jan.
[Is] ISSN:0004-0614
[Cp] País de publicação:Spain
[La] Idioma:spa
[Ab] Resumo:Risk factors should be evaluated in all patients with urinary lithiasis. The kind of evaluation, simplified or extended, depends on stone composition and, in patients with calcium lithiasis, on the clinical presentation. These studies are done in an outpatient regimen, are easy to perform and accessible for most laboratories. Patients with uric acid, infectious and cystine stones only require a selective more abbreviated evaluation. In calcium lithiasis we perform an extended metabolic evaluation in recurrent patients and also in singleepisode patients when they have high recurrence risk. The extended evaluation has demonstrated to be costeffective in patients with highly recurrent lithiasis. There is not enough clinical evidence yet on what would be the most convenient study methodology for a proper metabolic evaluation, and proposed clinical guidelines are mainly based on expert committee opinions.With these studies, we can diagnose systemic and renal diseases of lithogenic nature, and they also enable the adoption of precise prophylactic measures that achieve recurrence control in a great number of patients.
[Mh] Termos MeSH primário: Urolitíase/diagnóstico
Urolitíase/metabolismo
[Mh] Termos MeSH secundário: Algoritmos
Cálcio/análise
Técnicas de Diagnóstico Urológico
Seres Humanos
Hipercalciúria/complicações
Hiperoxalúria/complicações
Anamnese
Medição de Risco
Fatores de Risco
Urolitíase/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
SY7Q814VUP (Calcium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE


  5 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28124523
[Au] Autor:Guimaraes GC; Costa WH; Rosa RA; Zequi S; Favaretto R
[Ad] Endereço:Núcleo de Urologia, Departamento de Cirurgia Pélvica, AC Camargo Cancer Center, SP, Brasil.
[Ti] Título:Predictive role of Trimprob associated with multiparametric MRI in the diagnosis of prostate cancer.
[So] Source:Int Braz J Urol;43(1):29-35, 2017 Jan-Feb.
[Is] ISSN:1677-6119
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the predictive value of TRIMprob test to detect prostate cancer (PCa) in patients referred to prostate biopsy (PB). MATERIAL AND METHODS: Patients with PSA <10ng/mL and rectal exam without findings suggestive of prostate cancer were selected for TRIMprob evaluation. Exam was performed by a single operator through transperineal approach. Patients admitted for the study were submitted to TRIMprob and multiparametric magnetic resonance (mpMRI) and posteriorly to PB. RESULTS: In total, 77 patients were included. TRIMprob showed evidences of PCa in 25 (32.5%) and was negative in 52 patients (67.5%). The rate of detection of prostate cancer at biopsy was higher in patients with positive TRIMprob (16/25; 64.0%) than in patients with negative TRIMprob (11/52; 21.1%; p<0.001). Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of TRIMprob were respectively 61.5%, 82.0%, 64.0%, 80.3% and 74.0%. ROC curve showed the following areas under the curve values for TRIMprob, mpMRI and combination of TRIMprob + mpMRI: 0.706; 0.662 and 0.741 respectively. At combined analysis, when both TRIMprob and mpMRI were negative for prostate cancer, accuracy was 96.3% or only 1 in 27 PB was positive (3.7%). CONCLUSIONS: Trimprob had similar predictive value for PCa in patients submitted to PB as mpMRI. Combined TRIMprob and mpMRI showed higher accuracy than when performed singly.
[Mh] Termos MeSH primário: Técnicas de Diagnóstico Urológico/instrumentação
Imagem por Ressonância Magnética/métodos
Neoplasias da Próstata/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Distribuição por Idade
Idoso
Biópsia
Estudos Transversais
Seres Humanos
Masculino
Meia-Idade
Gradação de Tumores
Próstata/diagnóstico por imagem
Próstata/patologia
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/patologia
Valores de Referência
Reprodutibilidade dos Testes
Estudos Retrospectivos
Sensibilidade e Especificidade
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170127
[St] Status:MEDLINE


  6 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28075514
[Au] Autor:Bower WF; Rose GE; Ervin CF; Goldin J; Whishaw DM; Khan F
[Ad] Endereço:Department of Rehabilitation, Royal Melbourne Hospital, Parville, Vic., Australia.
[Ti] Título:TANGO - a screening tool to identify comorbidities on the causal pathway of nocturia.
[So] Source:BJU Int;119(6):933-941, 2017 Jun.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To develop a robust screening metric for use in identifying non-lower urinary tract comorbidities pertinent to the multidisciplinary assessment of patients with nocturia. METHODS: Variables having a significant risk association with nocturia of greater than once per night were identified. Discriminating items from validated and reliable tools measuring these comorbidities were identified. A self-completed 57-item questionnaire was developed and a medical checklist and pertinent clinical measures added. Pre-determined criteria were applied to retain or remove items in the development of the Short-Form (SF) screening tool. The tool was administered to 252 individuals with nocturia who were attending either a tertiary level Sleep, Continence, Falls or Rehabilitation service for routine care. Data collected were subjected to descriptive analysis; criteria were applied to reduce the number of items. Using pre-determined domains, a nocturia screening metric, entitled TANGO, was generated. The acronym TANGO stands for Targeting the individual's Aetiology of Nocturia to Guide Outcomes. RESULTS: The demographic characteristics of the sample are described, along with item endorsement levels. The statistical and structural framework to justify deleting or retaining of items from the TANGO Long-Form to the SF is presented. The resultant TANGO-SF patient-completed nocturia screening tool is reported. CONCLUSIONS: A novel all-cause diagnostic metric for identifying co-existing morbidities of clinical relevance to nocturia in patients who present across disciplines and medical specialties has been developed. TANGO has the potential to improve practice and smooth inequalities associated with a siloed approach to assessment and subsequent care of patients with nocturia.
[Mh] Termos MeSH primário: Noctúria/diagnóstico
Noctúria/etiologia
Autorrelato
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Autoavaliação Diagnóstica
Técnicas de Diagnóstico Urológico
Feminino
Seres Humanos
Masculino
Meia-Idade
Doenças Urológicas/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE
[do] DOI:10.1111/bju.13774


  7 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27840041
[Au] Autor:Gomez C; Bhatia S; Carnevale FC; Narayanan G
[Ad] Endereço:Department of Urology, University of Miami Miller School of Medicine, 1611 NW 12th Avenue #W279, Miami, Florida 33136.
[Ti] Título:Role of Urodynamic Studies in Management of Benign Prostatic Obstruction: A Guide for Interventional Radiologists.
[So] Source:J Vasc Interv Radiol;28(1):126-133, 2017 Jan.
[Is] ISSN:1535-7732
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Urodynamic testing is the most accurate representation of bladder outlet obstruction physiology. As prostate artery embolization becomes an increasingly common therapy for benign prostatic obstruction, knowledge of urodynamic assessment and reports can assist the interventional radiologist in selecting appropriate patients. This review summarizes the role of urodynamic studies in the management of benign prostatic obstruction, including patient selection, interpretation of urodynamic studies, and their potential to predict patient outcomes.
[Mh] Termos MeSH primário: Artérias
Técnicas de Diagnóstico Urológico
Embolização Terapêutica/métodos
Sintomas do Trato Urinário Inferior/diagnóstico
Próstata/irrigação sanguínea
Hiperplasia Prostática/diagnóstico
Radiografia Intervencionista
Radiologistas
Bexiga Urinária/fisiopatologia
Urodinâmica
[Mh] Termos MeSH secundário: Artérias/diagnóstico por imagem
Tomada de Decisão Clínica
Seres Humanos
Sintomas do Trato Urinário Inferior/fisiopatologia
Sintomas do Trato Urinário Inferior/terapia
Masculino
Nomogramas
Seleção de Pacientes
Valor Preditivo dos Testes
Hiperplasia Prostática/fisiopatologia
Hiperplasia Prostática/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161115
[St] Status:MEDLINE


  8 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27617867
[Au] Autor:Leitner L; Walter M; Jarrahi B; Wanek J; Diefenbacher J; Michels L; Liechti MD; Kollias SS; Kessler TM; Mehnert U
[Ad] Endereço:Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland.
[Ti] Título:A novel infusion-drainage device to assess lower urinary tract function in neuro-imaging.
[So] Source:BJU Int;119(2):305-316, 2017 Feb.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the applicability and precision of a novel infusion-drainage device (IDD) for standardized filling paradigms in neuro-urology and functional magnetic resonance imaging (fMRI) studies of lower urinary tract (LUT) function/dysfunction. SUBJECTS/PATIENTS AND METHODS: The IDD is based on electrohydrostatic actuation which was previously proven feasible in a prototype setup. The current design includes hydraulic cylinders and a motorized slider to provide force and motion. Methodological aspects have been assessed in a technical application laboratory as well as in healthy subjects (n=33) and patients with LUT dysfunction (n=3) undergoing fMRI during bladder stimulation. After catheterization, the bladder was pre-filled until a persistent desire to void was reported by each subject. The scan paradigm comprised automated, repetitive bladder filling and withdrawal of 100 mL body warm (37 °C) saline, interleaved with rest and sensation rating. Neuroimaging data were analysed using Statistical Parametric Mapping version 12 (SMP12). RESULTS: Volume delivery accuracy was between 99.1±1.2% and 99.9±0.2%, for different flow rates and volumes. Magnetic resonance (MR) compatibility was demonstrated by a small decrease in signal-to-noise ratio (SNR), i.e. 1.13% for anatomical and 0.54% for functional scans, and a decrease of 1.76% for time-variant SNR. Automated, repetitive bladder-filling elicited robust (P = 0.05, family-wise error corrected) brain activity in areas previously reported to be involved in supraspinal LUT control. There was a high synchronism between the LUT stimulation and the blood oxygenation level-dependent (BOLD) signal changes in such areas. CONCLUSION: We were able to develop an MR-compatible and MR-synchronized IDD to routinely stimulate the LUT during fMRI in a standardized manner. The device provides LUT stimulation at high system accuracy resulting in significant supraspinal BOLD signal changes in interoceptive and LUT control areas in synchronicity to the applied stimuli. The IDD is commercially available, portable and multi-configurable. Such a device may help to improve precision and standardization of LUT tasks in neuro-imaging studies on supraspinal LUT control, and may therefore facilitate multi-site studies and comparability between different LUT investigations in the future.
[Mh] Termos MeSH primário: Técnicas de Diagnóstico Urológico/instrumentação
Drenagem/instrumentação
Neuroimagem Funcional
Imagem por Ressonância Magnética
Bexiga Urinária/diagnóstico por imagem
Bexiga Urinária/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Desenho de Equipamento
Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170524
[Lr] Data última revisão:
170524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160913
[St] Status:MEDLINE
[do] DOI:10.1111/bju.13655


  9 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28247713
[Au] Autor:Alyaev YG; Bezrukov EA; Sirota ES; Morozov AO
[Ad] Endereço:I.M. Sechenov First Moscow State Medical University, Research Institute of Uronephrology and Human Reproductive Health, R.M. Fronshteyn Department and Clinic of Urology, Moscow.
[Ti] Título:[Indocyanine green fluorescent imaging in urology].
[So] Source:Urologiia;(1):106-110, 2016 Feb.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:This paper gives an overview of the prospects for indocyanine green fluorescent imaging, which is used in different fields of surgery, transplantation and urology. This method offers new opportunities in angiography, lymphography; it allows measuring tissue perfusion and differentiating healthy tissue and tumors in real time. The safety of the method has been proven and its diagnostic value is being extensively studied.
[Mh] Termos MeSH primário: Técnicas de Diagnóstico Urológico/instrumentação
Verde de Indocianina/uso terapêutico
Imagem Óptica
Doenças Urológicas/diagnóstico por imagem
[Mh] Termos MeSH secundário: Seres Humanos
Imagem Óptica/instrumentação
Imagem Óptica/métodos
[Pt] Tipo de publicação:LECTURES
[Nm] Nome de substância:
IX6J1063HV (Indocyanine Green)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE


  10 / 730 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27912839
[Au] Autor:Pfister C
[Ad] Endereço:Service d'urologie et de transplantation du rein, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen, France. Electronic address: christian.pfister@chu-rouen.fr.
[Ti] Título:[Urothelial tumors in 2016: Are we at the dawn of a new diagnostic and therapeutic era?]
[Ti] Título:Les tumeurs urothéliales en 2016 : sommes-nous aujourd'hui à l'aube d'une nouvelle ère diagnostique et thérapeutique ?.
[So] Source:Ann Pathol;36(6):369-370, 2016 Dec.
[Is] ISSN:0242-6498
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Oncologia/tendências
Neoplasias Urológicas/diagnóstico
Neoplasias Urológicas/terapia
Urologia/tendências
[Mh] Termos MeSH secundário: Vacina BCG/uso terapêutico
Cistectomia
Técnicas de Diagnóstico Urológico/tendências
Seres Humanos
Imunoterapia/tendências
Neoplasias Urológicas/classificação
Neoplasias Urológicas/patologia
[Pt] Tipo de publicação:EDITORIAL; INTRODUCTORY JOURNAL ARTICLE
[Nm] Nome de substância:
0 (BCG Vaccine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161204
[St] Status:MEDLINE



página 1 de 73 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde